BioCentury | Feb 6, 2020
Deals

Beyond Keytruda: How Merck envisions innovation and growth after a spinout

As Merck becomes the latest large pharma to split in two, separating its key growth drivers and innovative programs from its slower-growing businesses, the slimmed-down innovative company will rely on the fruits of recent and...
BioCentury | Jan 9, 2020
Product Development

Deals with Empirico and Aro to help Ionis bring new targets, tissues to early-stage pipeline

Ionis is turning to two young biotechs to build off the success of its antisense oligonucleotides and expand the reach of its platform. The company announced a pair of deals with Empirico and Aro on...
BC Extra | Dec 4, 2019
Company News

Dec. 3 Company Quick Takes: Brii adds neuroscience focus; plus Immunomedics, Hanmi-Rapt, Luye-Boan and Cara

Brii steps into neuroscience  Cross-border biotech Brii Biosciences said it will begin developing neuroscience programs as its second therapeutic area of interest, adding to its original focus on infectious diseases. The Beijing, China, and Durham,...
BC Extra | Sep 30, 2019
Company News

Sobi adding to U.S. presence, hematology pipeline via $915M Dova takeout

With the $915 million takeout of Dova Pharmaceuticals and a co-development deal with Sanofi in hemophilia, Sobi is continuing its push into the U.S. and strengthening its presence in hematology. Swedish Orphan Biovitrum AB (SSE:SOBI)...
BioCentury | Sep 11, 2019
Product Development

Pharmas’ challenge: learning from rare disease units while leaving them alone

How do you build a rare disease portfolio inside a pharma focused on large indications, and do right by both the new and the old? That’s a question faced by pharmas expanding from their traditional...
BC Extra | Aug 23, 2019
Company News

HotSpot acquires Macroceutics for focused allosteric library

HotSpot is adding a key piece to its allosteric inhibitor platform through the acquisition of DNA-encoded library company Macroceutics: the technology to make chemical libraries tailored to allosteric, rather than active, sites. The deal, announced...
BioCentury | Aug 10, 2019
Product Development

Eat this, don’t eat that: CD47 companies’ first hurdle

The rush to drug CD47 shows no signs of abating, with five companies launching clinical programs for cancer this year and three moving forward on the back of encouraging Phase I data. The differentiator may...
BC Extra | Aug 10, 2019
Company News

Management tracks: Melinta, Editas, Accelerate, Santhera

John Johnson has resigned as CEO of Melinta Therapeutics Inc. (NASDAQ:MLNT). He will stay with the antibiotics company during the search for his successor. David Gill, a board member, was named chairman, replacing Kevin Ferro,...
BioCentury | Jul 13, 2019
Tools & Techniques

Broadening role for external control arms in clinical trials

External control arms are moving from theory to practice as drug developers begin to use them to make internal go/no-go decisions for clinical programs and to support regulatory applications. The field is largely split between...
BioCentury | May 30, 2019
Emerging Company Profile

Thrive’s quest to bring multicancer liquid biopsy test into routine clinical use

With Third Rock leading the way in a $110 million series A, newly launched Thrive is banking that a multi-analyte approach to liquid biopsy could give it an edge in creating a test that is...
Items per page:
1 - 10 of 340